Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01731951 · ClinicalTrials.gov registry record · Phase 2
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
A Phase 2 study of Primary Myelofibrosis and Secondary Myelofibrosis, sponsored by Geron Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT01731951 is a Phase 2 study of Primary Myelofibrosis and Secondary Myelofibrosis that has completed, run by Geron Corporation. The registered enrollment target is 80 participants, below the 118-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01731951, a Phase 2 study of Primary Myelofibrosis and Secondary Myelofibrosis, has completed, sponsored by Geron Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot clinical trial studies how well imetelstat sodium works in treating participants with primary or secondary myelofibrosis and other myeloid malignancies. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- DRUG Imetelstat
Study Locations (1)
Minnesota
- - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2012-10-29 |
| Est. Completion | 2018-05-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01731951
The ClinicalTrials.gov registry entry for NCT01731951 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 118-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (32% lower). The listed sponsor is Geron Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Primary Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which Imetelstat is the first listed.
NCT01731951 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT01731951 about?
NCT01731951 is a clinical study titled "Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis". This pilot clinical trial studies how well imetelstat sodium works in treating participants with primary or secondary myelofibrosis and other myeloid malignancies. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01731951?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2012-10-29. Estimated completion is 2018-05-24.
What conditions does trial NCT01731951 study?
This clinical trial studies the following conditions: Primary Myelofibrosis, Secondary Myelofibrosis, Myeloid Malignancies.
What interventions are being tested in trial NCT01731951?
The interventions under investigation include: Imetelstat (DRUG).
Who is sponsoring clinical trial NCT01731951?
This trial is sponsored by Geron Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01731951 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
RECRUITING · Phase 2
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Study of Canakinumab in Patients With Myelofibrosis
RECRUITING · Phase 2
-
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
RECRUITING · Phase 2
-
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
RECRUITING · Phase 2
-
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.